Ashwin Mallya: Bladder Cancer Care is No Longer a Solo Act
Ashwin Mallya, Consultant Urologist and Robotic Surgeon at Sir Ganga Ram Hospital, shared a post on LinkedIn by Shiva Nafisi, Master Thesis Student at Università degli Studi di Milano, adding:
“Just wrapped up an energizing and insightful evening discussing ‘Modern Management of Bladder Cancer: Multidisciplinary Perspectives‘ — an ASCO-endorsed CPOEM Foundation webinar that brought together brilliant minds from across the globe.
It was a privilege to share the stage with
- Dr. Daniel Petrylak – Yale School of Medicine
- Dr. Guru Sonpavde – Advent Health Cancer Institute
- Dr. Vishwanath Sathyanarayanan
In my talk, I explored the surgical nuances of radical cystectomy in 2025 — from the evolving role of robotic surgery and ERAS protocols to real-world experience on urinary diversions, lymphadenectomy, and operating after neoadjuvant therapy. In addition how bladder preservation strategies come into play.
The session was a reminder that bladder cancer care is no longer a solo act — it’s a symphony of surgery, systemic therapy, and patient-centered decisions, played best when the urologist and medical oncologist are in harmony.
Grateful to the co-panelists, and the organising team who made the discussion so interactive. The future of bladder cancer care looks brighter when we think — and act — together. More so when 130+ Doctors attended it from across geographic divides.”
Quoting Shiva Nafisi‘s post:
“I had the pleasure of attending today’s ASCO endorsed CPOEM foundation webinar focused on advancements in bladder cancer management. The session brought together expert insights, clinical data, and evolving strategies that are shaping the future of urothelial carcinoma care.
The webinar covered a wide spectrum—from foundational procedures like TURBT and bladder mapping, to complex decision-making in NMIBC and muscle-invasive disease. Enhanced imaging techniques such as PDD, NBI, and CLE were highlighted for their role in improving tumor detection and resection quality.
Treatment pathways were discussed in depth, including intravesical therapies, radical cystectomy, and various urinary diversion options. The importance of neoadjuvant chemotherapy was reinforced through trials like VESPER, showing ddMVAC’s superior pathological response compared to Gem-Cis.
Immunotherapy and targeted agents are rapidly transforming the landscape. The NIAGARA trial demonstrated improved outcomes with Durvalumab + NAC, while newer FGFR3-specific inhibitors like LOXO-435 and TYRA-300 offer promising selectivity and efficacy. HER2-directed therapies and novel ADCs are also expanding options for advanced disease.
The role of ctDNA in guiding treatment decisions and monitoring minimal residual disease was another exciting frontier discussed.
Overall, the webinar was a rich learning experience—combining evidence-based practice with cutting-edge research. I’m thankful to the organizers and Daniel Petrylak, Guru Sonpavde, and Vishwanath Sathyanarayanan sharing their expertise and for creating a space where education and collaboration thrive.”
More posts featuring CPOEM Foundation on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023